Carboplatin plus Paclitaxel in the Successful Treatment of Advanced Inflammatory Myofibroblastic Tumor

Naoki Kubo; Taishi Harada; Satoshi Anai; Kohei Otsubo; Yasuto Yoneshima; Kayo Ijichi; Takaomi Koga; Koichi Takayama; Yoichi Nakanishi

doi:10.2169/internalmedicine.51.7599

CASE REPORTS

Carboplatin plus Paclitaxel in the Successful Treatment of Advanced Inflammatory Myofibroblastic Tumor

Naoki Kubo, Taishi Harada, Satoshi Anai, Kohei Otsubo, Yasuto Yoneshima, Kayo Ijichi, Takaomi Koga, Koichi Takayama, Yoichi Nakanishi

Author information

Keywords: inflammatory myofibroblastic tumor, chemotherapy, carboplatin, paclitaxel

JOURNAL OPEN ACCESS

2012 Volume 51 Issue 17 Pages 2399-2401

DOI https://doi.org/10.2169/internalmedicine.51.7599

Details

Abstract

A 26-year-old man with unresectable inflammatory myofibroblastic tumor (IMT) presented with multiple metastases in the thoracic vertebra and lymph nodes as detected by positron emission tomography (PET) received chemotherapy with carboplatin plus paclitaxel. After three cycles of chemotherapy, fluorine-18-fluorodeoxyglucose (FDG)-PET/CT revealed tumor regression and significant reduction of FDG uptake in all lesions. The patient received six cycles of chemotherapy without any severe adverse event, and there was no sign of disease progression for seven months. This regimen is well tolerated and may be considered the treatment of choice for unresectable IMT.

Corresponding author

Register with J-STAGE for free!